2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3164 Long-term clinical outcomes of aplastic anemia patients with acquired 6p copy number-neutral loss of heterozygosity (6pLOH)

HeeJin Cheon, MD, PhD, Jenna Ledley2, Nathan Gray, PA-C3, Marcin W Wlodarski, MD, PhD4, Timothy S. Olson, MD, PhD5, Daria V. Babushok Jr, MD, PhD6
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Acquired aplastic anemia (AA) is an autoimmune bone marrow failure disorder caused by T-cell-mediated destruction of early hematopoietic cells. Immune selection promotes clonal hematopoiesis, including copy-number-neutral loss of heterozygosity of chromosome arm 6p (6pLOH), which selectively eliminates HLA alleles implicated in autoimmune pathogenesis in approximately 12% of AA patients. Although 6pLOH represents immune escape in AA, its prognostic significance remains uncertain. We performed a retrospective multicenter study to evaluate long-term outcomes of AA patients with acquired 6pLOH.

32 AA patients with acquired 6pLOH were identified across three institutions. 6pLOH was observed on first available testing: 17 at diagnosis and 15 after a median of 3.9 years (0.1-10.8). 6pLOH region included HLA class I genes in 31 patients, while 1 had 6pLOH involving HLA class II but not HLA class I genes. Of 30 patients with available HLA typing, 10 had HLA-B*14:02, 2 had HLA-B*40:02, and 15/20 others carried one or more other HLA class I risk alleles. 6pLOH clones involved >50% of hematopoietic cells in 6 (18.8%), 20%–50% in 9 (28.1%), and <20% in 17 (53.1%) patients.

22 patients (68.8%) had severe AA (SAA), 2 (6.3%) very severe AA (VSAA), and 8 (25.0%) non-severe AA (NSAA). 5 had cytopenias for >1 year before AA diagnosis. AA was diagnosed at a median of 17.5 years (range 3–75), and patients were followed for a median of 6.8 years (range 0.2–23.2), with 30/32 alive at analysis.

Of 24 patients with SAA/VSAA, 17 (70.8%) received first-line ATG-based IST (5 with eltrombopag or romiplostim), 1 (4.1%) received cyclosporine (CSA)/danazol before ATG-based IST, 5 (20.8%) underwent upfront bone marrow transplantation (BMT), and one received prednisone/eltrombopag for presumed ITP before AA diagnosis. Of evaluable patients treated upfront with ATG-based IST, time to treatment was 42 days (range 0–153 days). At 3 months, 3 (18.8%) achieved PR, 2 (12.5%) CR, and 11/16 (68.8%) had no response. At 6 months, 3 (20.0%) had PR, 4 (26.7%) CR, and 8/15 (53.3%) no response. After a median follow-up of 7.5 years (range, 0.4-23.2) for the SAA/VSAA group, 7 (41.2%) experienced a relapse, 4 (23.5%) required a second ATG course for refractory/relapsed AA, and 10 (58.8%) underwent salvage BMT with 2 deaths from transplant-related complications.

Of 8 patients with NSAA, 5 (62.5%) had spontaneous remission with stable/improving blood counts without treatment, 2 (25.0%) received CSA (1 with eltrombopag) and 1 (12.5%) received ATG-based IST. After a median follow-up of 4.7 years (range, 0.27–15.0), 5 patients remained in remission, while 3 relapsed: 2 after CSA, and 1 relapsed with SAA over 6 years after initial spontaneous remission, with acquired 6pLOH, ETV6 and 2 DNMT3A variants identified at relapse.

Clonal evolution was frequent: somatic mutations were identified in 7 of 27 evaluable patients (25.9%), abnormal cytogenetics developed in 3 (9.4%), and PNH clones were detected in 12 patients, including 1 requiring complement inhibition. Among 13 patients with serial 6pLOH testing, three adults lost detectable 6pLOH after 1.1–6.7 years, each in association with clonal replacement and progressive pancytopenia: high-risk CCUS with ASXL1, DNMT3A, RUNX1, and +21; high-risk CCUS with GNAS and del(20q); or expansion of a TET2-mutant clone in a patient with refractory SAA.

In this multicenter North American cohort of patients with AA enriched for high-risk HLA class I alleles, acquired 6pLOH was associated with heterogeneous long-term outcomes. Patients presenting with SAA/VSAA had high rates of primary IST failure, relapse, and subsequent clonal evolution, suggesting less favorable outcomes than expected based on published IST outcomes in SAA. Outcomes of NSAA were better, with 4/8 (50%) of NSAA patients having durable spontaneous remission. Our data show that while 6pLOH represents immune escape adaptations, development of these HLA-loss clones does not protect against adverse hematologic outcomes, which may be driven by other factors such as age and high-risk immunogenetics. These findings argue against interpreting 6pLOH alone as a favorable prognostic biomarker in severe AA. Future longitudinal studies across diverse immunogenetic backgrounds are needed to define how HLA genotypes, somatic HLA loss, coexisting clonal abnormalities, choice of therapy, and other patient and disease factors influence disease course and treatment response.

HeeJin Cheon, MD, PhD: No relevant conflicts of interest to declare.